Literature DB >> 1347251

Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.

S Gollapudi1, K Patel, V Jain, S Gupta.   

Abstract

To identify the role of protein kinase C (PKC) isoforms in multidrug resistance in tumor cells, we examined the PKC isoform pattern in the multidrug resistant P388/ADR cell line and studied the effect of down regulation of PKC isoforms on intracellular daunorubicin accumulation and P-glycoprotein expression. Using monoclonal antibodies to PKC alpha, beta and gamma and flow cytometry technique we showed that P388/ADR cells overexpressed PKC alpha and beta as compared to drug sensitive P388 cells. Prolonged treatment of P388/ADR cells with phorbol myristate acetate (PMA), a procedure that is known to down regulate PKC, resulted in the down regulation of total PKC activity and the PKC beta isoform (at the protein level) that was accompanied by the correction of daunorubicin accumulation in P388/ADR cells. The level of expression of P-glycoprotein in PMA treated cells was similar to that of untreated cells. These results suggest that PKC beta regulates the drug efflux function of P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347251     DOI: 10.1016/0304-3835(92)90200-f

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Effects of phosphorylation of P-glycoprotein on multidrug resistance.

Authors:  U A Germann; T C Chambers; S V Ambudkar; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

2.  Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro.

Authors:  E C Sha; M C Sha; S H Kaufmann
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Regulation of protein kinase C and role in cancer biology.

Authors:  G C Blobe; L M Obeid; Y A Hannun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 4.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 5.  Linker Domains: Why ABC Transporters 'Live in Fragments no Longer'.

Authors:  Robert C Ford; Dominic Marshall-Sabey; John Schuetz
Journal:  Trends Biochem Sci       Date:  2019-12-12       Impact factor: 13.807

6.  Disruption of cellular signaling pathways by daunomycin through destabilization of nonlamellar membrane structures.

Authors:  P V Escribá; M Sastre; J A García-Sevilla
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

7.  Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin.

Authors:  E Dolfini; T Dasdia; G Arancia; A Molinari; A Calcabrini; R J Scheper; M J Flens; M B Gariboldi; E Monti
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-07       Impact factor: 3.850

9.  Inhibition of protein kinase C-alpha isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure.

Authors:  C A La Porta; E Dolfini; R Comolli
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.